Biohaven Ltd (BHVN)

$38.33

-0.66

(-1.69%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Biohaven Ltd

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 279.3%

Performance

  • $38.26
    $39.53
    $38.33
    downward going graph

    0.18%

    Downside

    Day's Volatility :3.21%

    Upside

    3.04%

    downward going graph
  • $12.35
    $62.21
    $38.33
    downward going graph

    67.78%

    Downside

    52 Weeks Volatility :80.15%

    Upside

    38.39%

    downward going graph

Returns

PeriodBiohaven LtdIndex (Russel 2000)
3 Months
-19.29%
0.0%
6 Months
45.21%
0.0%
1 Year
181.11%
-1.3%
3 Years
-47.9%
-22.1%

Highlights

Market Capitalization
3.2B
Book Value
$5.28
Earnings Per Share (EPS)
-5.73
Wall Street Target Price
59.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-46.39%
Return On Equity TTM
-84.44%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-429.1M
Diluted Eps TTM
-5.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.21
EPS Estimate Next Year
-5.95
EPS Estimate Current Quarter
-1.41
EPS Estimate Next Quarter
-1.39

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 55.23%

Current $38.33
Target $59.50

Technicals Summary

Sell

Neutral

Buy

Biohaven Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biohaven Ltd
Biohaven Ltd
-30.19%
45.21%
181.11%
-47.9%
-39.08%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biohaven Ltd
Biohaven Ltd
NA
NA
NA
-6.21
-0.84
-0.46
NA
5.28
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biohaven Ltd
Biohaven Ltd
Buy
$3.4B
-39.08%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Stifel Financial Corp

    7.63%
  • HHG PLC

    7.23%
  • BlackRock Inc

    7.06%
  • Suvretta Capital Management, LLC

    5.61%
  • State Street Corporation

    4.74%
  • T. Rowe Price Associates, Inc.

    3.84%

Corporate Announcements

  • Biohaven Ltd Earnings

    Biohaven Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Biohaven Ltd
Employees
239
CEO
Dr. Vladimir Coric M.D.
Industry
Health Technology

FAQs